For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

Video Presentation - VT28

2590

Dr.Sunayana N Murthy
Membership No Author Name Email Mobile
2590 Dr.Sunayana N Murthy sunayananm@gmail.com 9945042064
Anterior Segment

CRACKING THE CORNEAL FIBROSIS - LOSARTAN MAGIC!

To assess clinical and imaging outcomes of corneal scars treated with topical losartan (0.8 mg/mL) for 6 months, targeting TGF-β–mediated fibrosis.In this  study, 45 eyes were evaluated with etiologies mainly scars post fungal keratitis, post corneal tear and post refractive surgery. Losartan stock was aseptically prepared, 0.2 µm filter-sterilized, labelled, and sterility-verified before use at our lab. Patients received losartan drops 6 times daily for 6 months. Drop comfort and side effects were recorded.At 3 months, mean BCVA improved from 0.25 ± 0.17 to 0.17 ± 0.09 logMAR. Visual acuity improved in 35 eyes, stable in 10. OCT showed reduced scar depth and densitometry in 35 eyes. No significant side effects were noted.Topical losartan may reduce corneal fibrosis by inhibiting TGF-β pathways, improving clarity and scar depth.Losartan could serve as an affordable adjunctive therapy to enhance visual outcomes in patients with ocular scars.

Membership No Author Name Email Mobile
865 Prof.Rohit Shetty drrohitshetty@yahoo.com 9611102568
Non Member Dr.swaminathan setu swaminathansethu@narayananethralayna.com 9840343313